GSK plc announced that it has entered an agreement to acquire Nuvalent, Inc. a Boston-based clinical-stage biopharmaceutical company focused on creating precisely targeted oncology therapies, for $10.6 billion. The acquisition is consistent with GSK’s strategy of acquiring assets that have validated...
